Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Verizon raises its dividend with a high yield, while Johnson & Johnson offers steadier growth and a long payout histo...